*Should* MDMA-AT Be Saved? Part III

"Harms and misconduct will scale if they are allowed to train and certify therapists."

Welcome to The Frontier Psychiatrists. In part I, we covered what PTSD is and how Lykos Therapeutics, formerly MAPS PBS, submitted a novel combination of MDMA and “Assisted Therapy” with their branded (and also brand-new) therapy manual intended for that therapy to the FDA for the treatment of PTSD.

In Part II, I addressed the absurdity of the proposal on the part of MAPS PBC’s now deposed-ish founder, Rick Doblin, Ph.D, that all MDMA therapists take the drugs as part of their “training.”

Today is part III in out series on MDMA-AT, it’s FDA process, post-traumatic stress disorder, and the unsettling details coming to light about what allegedly happened in the clinical trials for a FDA-breakthrough pathway novel therapeutic.

What Did The FDA Advisory Committee Hear?

Many of those sharing their stories with the FDA highlighted the least recognized domain of PTSD symptoms—a pervasive change in thinking about the world and one’s self toward the negative. Mistrust, fear, dread, and anger bec…